Sanofi's Zika Standoff: Bad Medicine?

Published: Aug 11, 2017

Sanofi (NYSE: SNY) has had a bumper year thus far. Its revenue has exceeded analysts’ expectations and its share price jumped more than 20% YTD. It has outperformed the S&P 500 as well as the NYSE ARCA Pharmaceutical Index. That performance means Sanofi has successfully dodged the struggles plaguing other pharmaceutical firms after the shenanigans surrounding the late American Health Care Act. But a series of scandals and changing political attitudes have sounded alarm bells for the company’s fortunes.

Back to news